388610.KQ GFC Life Science Co., Ltd

Healthcare Biotechnology KOSDAQ
4,275 KRW
Close of Oct 30, 2026
4,050 17,220
Market cap
KRW 22.7B
P/E
22.0x
P/B
0.91x
ROE
7.2%
Dividend yield
-
Fundamental score
2.0/5

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is 388610.KQ undervalued?

Graham number
Price4,275
Graham value4,532
Discount5.7%

388610.KQ trades 5.7% below its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

GFC Life Science Co., Ltd fundamental analysis

10 of 22 checks passed

ROE 0/2

Low return on equity (7.2%), below 10%.

ROA 1/1

Return on assets (4.8%) is above the industry median (-10.1%).

Profit Consistency 0/2

Not profitable for at least 3 consecutive years.

Earnings Growth 5Y 0/1

Earnings per share history is shorter than 5 years.

Earnings Acceleration 0/1

Not enough positive earnings history to compare last year's growth with the 5-year average.

Earnings Growth vs Industry 1/1

Last year's EPS growth (107.8%) is above the industry median (4.8%).

Revenue Growth 0/2

Revenue did not grow over the past 3 years or is not reported.

Short-term Liquidity 1/1

Current assets cover short-term liabilities.

Long-term Liabilities 1/1

Current assets cover long-term liabilities.

Debt to Equity 2/2

Low debt to equity (36.9%), 40% or less.

Debt Trend 0/1

Debt to equity history is shorter than 5 years.

Debt Coverage 1/1

Operating cash flow covers 20% of total debt.

Interest Coverage 1/1

EBIT is 7.1x against interest expense, well covered.

PE vs Market 0/1

PE (22.0x) is above the market median (11.3x).

PE vs Industry 1/1

PE (22.0x) is below the industry median (28.9x).

PBV 1/1

Price to book (0.9x) is below the industry median (2.4x).

Graham Number 1/1

The price is below the Graham number (PE x PB = 20.0, limit 22.5).

PEG 0/1

PEG needs positive PE and positive 5-year earnings growth.

Dividend Yield 0/2

No dividend paid in the last reported year.

Dividend Stability 0/2

Dividends were not paid steadily for the past 5 years.

Dividend Growth 0/1

Dividends paid did not grow over the past 5 years.

Payout Ratio 0/1

No dividend, or no profit to pay it from.

Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score

GFC Life Science Co., Ltd stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About GFC Life Science Co., Ltd

GFC Life Science Co., Ltd develops cosmetic, food, and medical materials. The company develops bio-materials in the areas of human bio-technology, bio-phytochemistry, bio-fermentation, unique bio-technology, and biocompatible formula technology. It also offers scientific and systematic research services on human application testing. The company was formerly known as GFC Co., Ltd and changed its name to GFC Life Science Co., Ltd in 2018. GFC Life Science Co., Ltd was founded …

Full company profile